The $50K raise is trivial but signals 3i, LP is continuing to draw down on its existing preferred purchase agreements. Combined with the S-3 shelf filed same day, expect further dilutive capital raises. Monitor the S-3 for a potential at-the-market offering or follow-on.
Price Chart
Executive Summary
Valion Bio issued 50 Series B Preferred Shares and warrants to purchase 1,539 shares of common stock to activist investor 3i, LP for $50,000 under an existing purchase agreement. The tiny $50,000 raise comes amid a series of recent 3i, LP 13D/A filings and a same-day S-3 shelf filing, signaling ongoing capital needs and activist pressure.
Key Financial Metrics
Key Facts
- Issued 50 Series B Preferred Shares and warrants for 1,539 common shares at $2.5520 per share to 3i, LP for $50,000 total.
- 3i, LP has been actively purchasing VBIO common stock in recent weeks (Sept 2-3, 2026) at prices between $2.88 and $2.92.
- 3i, LP still has options to purchase up to $1.65M in Series B and up to $23.86M in Series C preferred shares.
- 3i, LP also holds a $16.25M Senior Secured Convertible Note with a warrant for 182,129 common shares.
- A same-day S-3 shelf filing was made, indicating potential for further capital raises.
- The company's CEO is listed as 'Interim' (Dean Zikria), suggesting leadership instability.
Financial Impact
Minimal immediate cash infusion of $50,000; existing debt and preferred overhang of ~$29.6M (Series B $1.65M + Series C $13.6M + Note $16.25M) plus warrant overhang for 182,129+ shares.
Risk Factors
- Significant existing convertible debt ($16.25M senior secured note) and preferred stock overhang (~$29.6M total potential) creates persistent dilution risk.
- Activist 3i, LP has multiple levers (preferred, warrants, note) to exert pressure or force conversion, potentially flooding the market with common shares.
- Interim CEO and repeated small-dollar raises suggest the company is struggling to secure meaningful financing on favorable terms.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007709 |
| Document: valion_ex1001.htm | 0001683168-26-007709 |
| Document: 0001683168-26-007709-index-headers.html | 0001683168-26-007709 |
| Document: 0001683168-26-007709-index.html | 0001683168-26-007709 |
| Document: 0001683168-26-007709.txt | 0001683168-26-007709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers